FAQ

FAQ published on August 20, 2014
Dr. Hutchings discusses the various global trials that are showing results of the benefit of PET-CT scans on when, how, and what regimen to use when treating a Hodgkin lymphoma patient.
FAQ published on April 22, 2014
Dr. von Tresckow discusses the unique challenges of treating elderly or advanced-age patients.
FAQ published on April 22, 2014
Dr. Hutchings discusses how PET-CT can be used in selecting therapy for patients with both early and advanced-stage Hodgkin lymphoma.
FAQ published on April 22, 2014
Dr. Federico discusses the potential of chemotherapy-induced infertility with men and women.
FAQ published on April 10, 2014
Dr. Cavalli discusses therapeutic options for an elderly patient, defined as 65 years and over, a demographic susceptible to lethal toxicity from agents.
FAQ published on April 10, 2014
Dr. von Tresckow discusses treatment options for relapsed/refractory Hodgkin lymphoma.
FAQ published on April 9, 2014
Dr. Tim Illidge discusses radiotherapy as part of a standard of care in Hodgkin lymphoma patients.
FAQ published on April 9, 2014
Dr. Steidl discusses microenvironments and the significance in the molecular pathogenesis of Hodgkin lymphoma.
FAQ published on March 21, 2014
Dr. Borchmann discusses the efficacy and safety of long-term treatment that includes involved field radiotherapy.
FAQ published on March 5, 2014
Dr. Engert discusses the treatment regimen BEACOPP escalated and the occurrence of acute leukemia and myelodysplasia after treatment.
Page 4 of 6
Results 31 - 40 of 56

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved